Progesterone Containing Contraceptive Methods on Endogenous Progesterone Level
NCT ID: NCT05742503
Last Updated: 2023-02-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
80 participants
OBSERVATIONAL
2021-03-30
2022-03-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Female Sexual Functions With Progestogen-only Contraception
NCT02579590
Hysteroscopic Findings in Women Using Progesterone Only Pills (Minipills)
NCT05024604
PROMES: A Clinical Study in Which Researchers Want to Learn More About the Safety Profile of MESIGYNA (Norethisterone Enantate 50 mg and Estradiol Valerate 5 mg) Used as a Medication to Prevent Pregnancy for Adult Women in Reproductive Age in the Peruvian Population at the Outpatient Clinic.
NCT03901131
The Value of Oral Micronized Progesterone in the Prevention of Spontaneous Preterm Birth
NCT02571296
Endometrial Biopsy in Progestin Contraceptive Users
NCT05760144
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Intrauterine, injectable methods and contraceptive implants named as long-acting reversible contraceptives (LARC) are the more efficient reversible contraceptive approaches are highly effective, longer-acting contraceptive methods levels.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Depo-Provera group
This group will receive150 mg of injectable progesterone every 90 days or 3 months
Depo-Provera
Injectable progesterone
Implanon group
This group will receive 68 mg of etonogestrel implant formerly known as Implanon.
Implanon
Etonogestrel implant
Norgestrel group
This group will receive 0.075 mg of norgestrel (Ovrette®) once daily.
Norgestrel
Pill containing progesterone
Mirena group
This group will receive IUD (Mirena) containing 52 mg of levonorgestrel.
Mirena
Levonorgestrel-releasing intra-uterine drug (IUD)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Depo-Provera
Injectable progesterone
Implanon
Etonogestrel implant
Norgestrel
Pill containing progesterone
Mirena
Levonorgestrel-releasing intra-uterine drug (IUD)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 20-35 years
* With normal menstrual history
* Had at least one offspring after spontaneous pregnancy
Exclusion Criteria
* Ovarian tumors
* submucous myoma
* irregular menstrual cycle
* past or family history of breast disease
* Diabetic patients,
* medication affecting reproductive or metabolic functions.
* endometrial thickness \<7 mm on the secretory transformation day
* history of spontaneous abortions
* history of embryo transfer failure on over three occasions
* Patients had cortisol medications
* patients who received radiological treatment
20 Years
35 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tanta University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ahmed Ossman
Assistant Professor of Obstetrics and Gynecology Department,Faculty of Medicine,Tanta University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mona K Omar, MD
Role: PRINCIPAL_INVESTIGATOR
Assistant Professor of Obstetrics and Gynecology Department, Faculty of Medicine,Tanta University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ahmed Ossman
Tanta, El-Gharbia, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
36035/11/22
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.